HUE046740T2 - Készítmények és eljárások ptosis (szemhéjcsüngés) nem-mûtéti kezelésére - Google Patents

Készítmények és eljárások ptosis (szemhéjcsüngés) nem-mûtéti kezelésére

Info

Publication number
HUE046740T2
HUE046740T2 HUE12709421A HUE12709421A HUE046740T2 HU E046740 T2 HUE046740 T2 HU E046740T2 HU E12709421 A HUE12709421 A HU E12709421A HU E12709421 A HUE12709421 A HU E12709421A HU E046740 T2 HUE046740 T2 HU E046740T2
Authority
HU
Hungary
Prior art keywords
ptosis
preparations
methods
surgical treatment
eyelid sagging
Prior art date
Application number
HUE12709421A
Other languages
English (en)
Hungarian (hu)
Inventor
Mark Silverberg
Original Assignee
Voom Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voom Llc filed Critical Voom Llc
Publication of HUE046740T2 publication Critical patent/HUE046740T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D47/00—Closures with filling and discharging, or with discharging, devices
    • B65D47/04—Closures with discharging devices other than pumps
    • B65D47/06—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages
    • B65D47/18—Closures with discharging devices other than pumps with pouring spouts or tubes; with discharge nozzles or passages for discharging drops; Droppers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HUE12709421A 2011-03-03 2012-02-24 Készítmények és eljárások ptosis (szemhéjcsüngés) nem-mûtéti kezelésére HUE046740T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161448949P 2011-03-03 2011-03-03
US13/218,584 US20120225918A1 (en) 2011-03-03 2011-08-26 Compositions and Methods for Non-Surgical Treatment of Ptosis
US13/270,577 US8357714B2 (en) 2011-03-03 2011-10-11 Compositions and methods for non-surgical treatment of ptosis

Publications (1)

Publication Number Publication Date
HUE046740T2 true HUE046740T2 (hu) 2020-03-30

Family

ID=46753678

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12709421A HUE046740T2 (hu) 2011-03-03 2012-02-24 Készítmények és eljárások ptosis (szemhéjcsüngés) nem-mûtéti kezelésére

Country Status (24)

Country Link
US (8) US20120225918A1 (https=)
EP (2) EP3653205A3 (https=)
JP (1) JP6106100B2 (https=)
KR (1) KR101889392B1 (https=)
CN (1) CN103501771B (https=)
AU (1) AU2012223615B2 (https=)
BR (1) BR112013022094A2 (https=)
CA (1) CA2827285C (https=)
CY (1) CY1122565T1 (https=)
DK (1) DK2680829T3 (https=)
ES (1) ES2750123T3 (https=)
HR (1) HRP20192266T1 (https=)
HU (1) HUE046740T2 (https=)
LT (1) LT2680829T (https=)
MX (1) MX345042B (https=)
PL (1) PL2680829T3 (https=)
PT (1) PT2680829T (https=)
RS (1) RS59636B1 (https=)
RU (1) RU2582392C2 (https=)
SG (1) SG192801A1 (https=)
SI (1) SI2680829T1 (https=)
SM (1) SMT201900718T1 (https=)
WO (1) WO2012118704A1 (https=)
ZA (1) ZA201307262B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MX357635B (es) 2011-09-20 2018-07-17 Allergan Inc Composiciones y metodos para el tratamiento de presbicia, hipermetropia leve, y astigmatismo irregular.
BR112015027984A2 (pt) * 2013-05-06 2017-09-05 Allergan Inc Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
CA2869060A1 (en) * 2014-07-28 2016-01-28 Queen's University At Kingston Dosage forms and methods for diagnosing sympathetic nervous system dysfunction
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
WO2017132410A1 (en) * 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
CN106726115B (zh) * 2016-12-22 2023-01-20 上海交通大学医学院附属第九人民医院 一种眼睑功能矫正器
CN106938039A (zh) * 2017-03-29 2017-07-11 卢仁华 眼睑下垂的治疗药物
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN108635434A (zh) * 2018-06-24 2018-10-12 吴安相 一种治疗眼睑下垂的侗族中药配方
AU2019390704A1 (en) * 2018-11-26 2021-06-03 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
US20230218726A1 (en) * 2020-04-23 2023-07-13 Okogen, Inc. Treatment of viral conjunctivitis
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1117588B (de) 1960-09-30 1961-11-23 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates
US3670087A (en) * 1970-10-16 1972-06-13 Miles Lab Method of lowering intraocular pressure
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
DE3227741A1 (de) 1982-07-24 1984-01-26 Hoechst Ag, 6230 Frankfurt 1-phenyl-isochinolinderivate und verfahren zu ihrer herstellung
FR2549015B1 (fr) * 1983-07-13 1986-06-13 Oreal Ensemble compte-gouttes
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
AU7081598A (en) * 1997-04-24 1998-11-13 Taisho Pharmaceutical Co., Ltd. Eye drops
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US5885550A (en) * 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
TWI283669B (en) * 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
WO2002026223A2 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US7780976B2 (en) * 2002-05-30 2010-08-24 Eye Care And Cure, Asia Apparatus and method for delivering controlled quantities of one or more agents to the eye
JP2005533076A (ja) * 2002-06-20 2005-11-04 ノバルテイス・コンシユーマー・ヘルス・エス・アー ムコ多糖及びプロピレングリコールを含む鼻用組成物
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US7022740B2 (en) 2004-04-29 2006-04-04 Leonard Mackles Lubricious ophthalmic solutions
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
JP4942328B2 (ja) * 2004-11-01 2012-05-30 ロート製薬株式会社 ビタミンｂ６類含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4956981B2 (ja) * 2005-01-05 2012-06-20 大正製薬株式会社 オキシメタゾリン含有水性組成物
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
JP2009535342A (ja) * 2006-04-26 2009-10-01 アーシエックス， インコーポレイテッド 眼瞼腫脹の予防および処置のための組成物
WO2008070185A2 (en) 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
AU2008325214A1 (en) * 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
CA2755679C (en) * 2009-03-17 2017-09-12 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
MX2011013060A (es) 2009-06-05 2012-02-28 Aciex Therapeutics Inc Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
WO2012017077A1 (en) 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases
JP6030067B2 (ja) 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的クリーム組成物および使用法
BR112013020770A2 (pt) * 2011-02-15 2019-08-27 Allergan, Inc. composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
AU2013266067B2 (en) 2012-05-25 2016-10-06 Xlear, Inc. Xylitol-based anti-mucosal compositions and related methods and compositions
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
MX379253B (es) 2014-06-11 2025-03-11 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos.
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
US20190000808A1 (en) * 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Also Published As

Publication number Publication date
LT2680829T (lt) 2019-12-27
JP6106100B2 (ja) 2017-03-29
EP3653205A3 (en) 2020-08-26
KR101889392B1 (ko) 2018-08-17
CN103501771A (zh) 2014-01-08
EP2680829A1 (en) 2014-01-08
US20220218669A1 (en) 2022-07-14
SI2680829T1 (sl) 2020-02-28
KR20140013013A (ko) 2014-02-04
BR112013022094A2 (pt) 2017-06-27
RS59636B1 (sr) 2020-01-31
US20120225919A1 (en) 2012-09-06
ZA201307262B (en) 2015-02-25
US8357714B2 (en) 2013-01-22
US10912765B2 (en) 2021-02-09
HRP20192266T1 (hr) 2020-03-20
WO2012118704A1 (en) 2012-09-07
NZ614719A (en) 2015-05-29
CN103501771B (zh) 2016-05-11
US9018240B2 (en) 2015-04-28
PT2680829T (pt) 2019-12-10
US20120225920A1 (en) 2012-09-06
CA2827285A1 (en) 2012-09-07
RU2582392C2 (ru) 2016-04-27
DK2680829T3 (da) 2019-11-18
US20200360345A1 (en) 2020-11-19
MX2013009597A (es) 2014-01-08
US20120225918A1 (en) 2012-09-06
US9867808B2 (en) 2018-01-16
CY1122565T1 (el) 2021-01-27
PL2680829T3 (pl) 2020-03-31
MX345042B (es) 2017-01-16
US20160038465A1 (en) 2016-02-11
CA2827285C (en) 2019-05-07
ES2750123T3 (es) 2020-03-25
EP2680829B1 (en) 2019-09-25
AU2012223615B2 (en) 2017-03-02
SMT201900718T1 (it) 2020-01-14
EP3653205A2 (en) 2020-05-20
JP2014506927A (ja) 2014-03-20
RU2013142602A (ru) 2015-04-10
US20180338953A1 (en) 2018-11-29
US20200009114A1 (en) 2020-01-09
SG192801A1 (en) 2013-09-30
AU2012223615A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
HUE046740T2 (hu) Készítmények és eljárások ptosis (szemhéjcsüngés) nem-mûtéti kezelésére
IL272539B (en) Compositions and methods for immunotherapy
HUE036220T2 (hu) Kinazolin származékok vírusfertõzések és további betegségek kezelésére
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
HUE046963T2 (hu) Készítmények és kezelés szembetegségekhez és rendellenességekhez
IL236700A (en) History of alkylpyrimidine for the treatment of viral infections and other diseases
HUE036561T2 (hu) Készítmények rheumatoid arthritis kezelésére és eljárások alkalmazására
HUE045629T2 (hu) Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
HUE042271T2 (hu) Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
IL229143A0 (en) Titanium dioxide photocatalytic compositions and uses thereof
HUE053439T2 (hu) Sejtes immunterápiára szolgáló eljárás és készítmények
HUE044591T2 (hu) Anti-CD40 antitestek és alkalmazásuk
HUE044816T2 (hu) Készítmények és eljárások hajhullás kezelésére
HUE038759T2 (hu) Terápiás nukleázkészítmények és eljárások
PT2898885T (pt) Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
HUE040019T2 (hu) Hajnövekedést stimuláló készítmények és módszerek
HUE042516T2 (hu) Javított eljárás treprosztinilnek és származékainak elõállítására
ZA201502238B (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
IL233639B (en) Compositions and methods for the treatment of hepatic diseases and disorders
IL232710B (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
HUE037673T2 (hu) Szulfonil-piperidin-származékok és alkalmazásuk prokineticin-mediált betegségek kezelésére
HUE037870T2 (hu) Készítmények és módszerek lisztérzékenység kezelésére
EP3086809A4 (en) Compositions and methods of treating ocular diseases